This is a routine cashless exercise and sale by an officer, consistent with a pre-existing pattern of monthly option exercises. No material signal for the stock. Monitor for any acceleration in insider selling volume or unexpected insider departures.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 13 $26.86entry
- T+1 · 6mo ago 0.00%α +0.00% · $26.86
- T+5 · 6mo ago −3.09%α −1.93% · $26.03
- T+20 · 5mo ago −10.87%α −10.26% · $23.94
- T+60 · 3mo ago +1.82%α −2.61% · $27.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Officer David Malcom Rodman filed a Form 144 to sell 6,348 shares of Mineralys Therapeutics (MLYS) valued at approximately $186,348 via a broker-assisted cashless exercise of employee stock options. This is a small, routine insider sale relative to the company's $2.5B market cap and follows a pattern of regular monthly sales by the same insider, making it a low-impact event.
Key Facts
- Insider: Officer David Malcom Rodman
- Shares to sell: 6,348 shares of common stock
- Estimated value: ~$186,348
- Sale method: Broker-assisted cashless exercise of employee stock options
- Filing date: May 12, 2026
- Prior sales by same insider: 13 transactions since Feb 2026, totaling ~$2.0M
- Market cap: $2.5B
- Recent insider activity (30d): 4 sells totaling $984K
Financial Impact
Proposed sale of ~$186K, representing ~0.007% of market cap
Risk Factors
- Insider selling pattern could accelerate if stock price declines or negative news emerges
- Cashless exercises may indicate insider needs liquidity, not necessarily bearish view
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001964306-26-000234 |
| Document: 0001964306-26-000234-index.html | 0001964306-26-000234 |
| Document: 0001964306-26-000234.txt | 0001964306-26-000234 |
Track record
35 reports on MLYS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 10 went positive at some point.
Filters
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
- Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
- Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers